4.2 Acute Metabolic & Toxicological Emergencies

Acute Metabolic & Toxicological Emergencies

Metabolic derangements and acute drug toxicities are common presentations in emergency departments that require rapid recognition, stabilization, and target-specific therapies. This section focuses on the clinical management of Diabetic Ketoacidosis (DKA) versus Hyperosmolar Hyperglycemic State (HHS), and key toxicological interventions for paracetamol and opioid overdoses.

Diabetic Ketoacidosis (DKA) vs. Hyperosmolar Hyperglycemic State (HHS)

DKA and HHS are life-threatening acute metabolic complications of diabetes mellitus. While they overlap, they have distinct pathophysiological mechanisms and diagnostic profiles:

• Diabetic Ketoacidosis (DKA): Characterized by an absolute insulin deficiency combined with counterregulatory hormone excess (glucagon, catecholamines, cortisol). This state stimulates lipolysis, releasing free fatty acids that undergo hepatic beta-oxidation to form ketone bodies (acetoacetate, beta-hydroxybutyrate), resulting in systemic metabolic acidosis. Most common in Type 1 Diabetes.
• Hyperosmolar Hyperglycemic State (HHS): Characterized by a relative insulin deficiency. The remaining insulin is sufficient to prevent lipolysis and ketogenesis but insufficient to facilitate peripheral glucose utilization. This results in extreme hyperglycemia, massive osmotic diuresis, and profound intracellular and extracellular dehydration. Most common in Type 2 Diabetes.

---

DKA and HHS Management Protocols

The management of DKA and HHS is structured around four pillars: fluid resuscitation, insulin therapy, electrolyte correction (particularly potassium), and identifying the precipitating cause (e.g., infection, non-adherence, myocardial infarction).

1. Fluid Resuscitation

Fluid replacement is the most critical first step. It restores intravascular volume, improves renal perfusion (which enhances urinary glucose excretion), and reduces counterregulatory hormones.

• Initial Fluid: Administer 0.9% Normal Saline (NaCl) at 15-20 mL/kg/hour (typically 1-1.5 L in the first hour).
• Subsequent Fluid selection:
  • Check the corrected serum sodium: Corrected Sodium = Measured Sodium + 1.6 * ((Serum Glucose - 100) / 100).
  • If corrected sodium is normal or high: Switch to 0.45% NaCl at 250-500 mL/hour.
  • If corrected sodium is low: Continue 0.9% NaCl at 250-500 mL/hour.
• Dextrose Switch: When serum glucose drops below 250 mg/dL in DKA, or 300 mg/dL in HHS, change the IV fluids to 5% Dextrose in 0.45% NaCl (D5 1/2NS). This prevents rapid drops in serum osmolarity that can cause cerebral edema (especially in children) and allows the continued administration of insulin to shut down ketogenesis.

2. Insulin Therapy

Insulin is required to suppress lipolysis, resolve ketosis, and correct hyperglycemia.

• Dosing: Start a continuous IV infusion of Regular Insulin at 0.1 units/kg/hour (or a bolus of 0.1 units/kg followed by 0.1 units/kg/hour).
• Target: Aim for a steady glucose decline of 50-75 mg/dL/hour. If this is not achieved, check fluid status; if adequate, double the insulin infusion rate.
• Transition to Subcutaneous Insulin: Maintain the insulin infusion until DKA is resolved: pH > 7.30, bicarbonate >= 15 mEq/L, and anion gap <= 12 mEq/L. Ensure the patient is able to tolerate oral intake. Administer the first dose of subcutaneous rapid- or short-acting insulin (along with basal insulin) 2 hours before stopping the IV insulin infusion to prevent rebound ketosis. For HHS, continue insulin infusion until osmolarity is < 310 mOsm/kg, blood glucose is <= 250 mg/dL, and the patient has recovered their baseline mental status.

3. Potassium Replacement

Insulin administration drives potassium into the intracellular compartment, causing a rapid fall in serum potassium levels.

• If Potassium < 3.3 mEq/L: HOLD insulin. Administer IV potassium chloride (KCl) at 20-30 mEq/hour until the potassium level is > 3.3 mEq/L. Starting insulin in this state can precipitate fatal cardiac arrhythmias or diaphragmatic paralysis.
• If Potassium 3.3 - 5.2 mEq/L: Add 20-30 mEq of KCl to each liter of IV fluids to maintain serum potassium between 4.0 and 5.0 mEq/L. Continue insulin therapy.
• If Potassium > 5.2 mEq/L: Do not administer potassium. Monitor serum potassium every 2 hours.

---

Toxicological Emergencies

Paracetamol (Acetaminophen) Toxicity

Paracetamol is one of the most common accidental and intentional drug overdoses worldwide.

• Pathophysiology: Normally, paracetamol is metabolized via hepatic glucuronidation and sulfation. A small portion is metabolized by cytochrome P450 (specifically CYP2E1) to N-acetyl-p-benzoquinone imine (NAPQI), a highly reactive toxic metabolite. Under normal conditions, NAPQI is immediately detoxified by conjugation with glutathione. In overdose, the primary pathways become saturated, leading to glutathione depletion. Excess NAPQI then binds covalently to hepatocytes, causing centrilobular hepatic necrosis.
• Rumack-Matthew Nomogram: Used to assess the risk of hepatotoxicity following a single acute ingestion. Plot the serum paracetamol level against the time since ingestion (must be at least 4 hours post-ingestion). If the level falls on or above the treatment line (starting at 150 mcg/mL at 4 hours), treatment is indicated.
• Antidote: N-acetylcysteine (NAC). NAC acts as a glutathione precursor and direct substitute to neutralize NAPQI. It is most effective when administered within 8 hours of ingestion. It is typically given as a 21-hour IV infusion protocol or a 72-hour oral protocol.

Opioid Toxicity

Opioid overdose causes life-threatening respiratory depression due to activation of mu-opioid receptors in the brainstem respiratory center.

• Clinical Presentation (The Opioid Triad):
  1. Respiratory depression (decreased respiratory rate, often < 12/minute, and shallow breaths).
  2. Miosis (pinpoint pupils, though pupillary dilation can occur with severe hypoxia or co-ingestion of stimulants).
  3. Depressed level of consciousness (somnolence, stupor, or coma).
• Antidote: Naloxone.
• Goal of Therapy: The primary goal is to restore adequate spontaneous ventilation (respiratory rate > 12/minute, normal oxygenation) and airway protection, not to restore full consciousness. Aggressive dosing can precipitate acute withdrawal syndrome (severe agitation, nausea, vomiting, piloerection, tachycardia, and rare but severe non-cardiogenic pulmonary edema).
• Half-life Consideration: Naloxone has a short half-life of 30-90 minutes, which is often shorter than the half-life of the ingested opioid (e.g., methadone, sustained-release formulations). Close monitoring for recurrent respiratory depression is required, and repeat doses or a continuous infusion may be necessary.